Is the Behcet's disease a risk factor for osteoporosis and is relation to cytokines?

Bratislava Medical Journal

Volumn 111, Issue 6, 2010, Pages 340-344

  Kirnap, M ^a   Calis, M ^a   Kaya, N ^a   Muhtaroglu, S ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Behcet's disease; Cytokines; Osteopenia; Osteoporosis

Indexed keywords

CYTOKINE;

ADULT; ARTICLE; BEHCET DISEASE; BLOOD; BONE DENSITY; FEMALE; HUMAN; MALE; OSTEOPOROSIS; RISK FACTOR;

ADULT; BEHCET SYNDROME; BONE DENSITY; CYTOKINES; FEMALE; HUMANS; MALE; OSTEOPOROSIS; RISK FACTORS;

EID: 77956222432     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Sahin S, Lawrence R, Diriskeneli H et al. Monocyte activity in Behcet's Disease. J Rheumatol 1996; 35: 424-429.
2. Mege J, Dilsen N, Sanguedolce V et al. Overproduction of monocyte derived tumor necrosis factor α, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's Disease. A Comporative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-1549.
3. Iijima S, Otsuka F. Peripheral blood neutrophil rheology measured by micropore filtration reflects Behcet's disease activity well. J Dermatol Sci 1997; 15:44-50.
4. Zouboluis C, Katsantonis J, Ketteler R et al. Adamantiades-Behcet's disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res 2000; 292: 279-284.
5. Merly SL. Metabolic bone diseases. In: Kelly WH, Harris ED, Ruddy S, Sledge CB, Text book of Rheumatology. WB Saunders Company, Philadelphia 1997: 1563-1581.
6. Linsay R, Meunier PS. Diagnostic test for osteoporosis. Osteoporosis Int 1998; 4: 21-26.
7. Ersler WB, Harman SM, Keller ET. Immunologic aspects of osteoporosis. Dev Comp Immunol 1997; 21: 487-499.
8. Bicer A, Tursen U, Kaya TI et al. Bone mineral density in patient with Behcet's disease. Rheumatol Int 2004; 24: 355-358.
9. Ghate JV, Jorizzo JL. Behcet's disease and complex aphthosis. J Am Acad Dermatol 1999; 40: 1-18.
10. Emmi L, Brugnolo F, Marchione T. Pathogenesis and therapy of Behcet's disease. Ann Ital Med Int 1997; 12: 20-25.
11. Raisz LG, Kream BE, Lorenzo SA. Metabolic bone disease. In: Wilson JA, Foster DW (Eds). Williams Textbook of Endocrinology. WB Saundres Company, Philadelphia 1998; 1211-1239.
12. Taylor AK, Leuken SA, Libanati C et al. Biochemical markers of bone turnover for the clinical assesment of bone metabolism. Rheum Dis Clin North Au 1994; 20: 589-608.
13. Evereklioglu C, Er H, Türköz Y et al. Serum levels of TNF-α, IL-2R, IL-6 and IL-8 are increased and associated with elevated lipid pero-xidation in patients with Behcet's disease. Med Inf 2002; 11: 87-93.
14. Sayinalp N, Ozcebe Ol, Özdemir O et al. Cytokines in Behcet's disease J. Rheumatol 1996; 23 (2): 321-322.
15. Gur A, Denli A, Nas K et al. Possible pathogenetic role of new cytokines in postmenopausal osteoporosis and changes during calcitonin plus calcium therapy. Rheumatol Int 2002; 22: 194-198.
16. Pietschman P, Grisor J, Thien R et al. Immune phenotype and intracellular cytokine production of peripheral blood mononuclear cells from postmenopausal patients with osteoporotic fractures. Exp Gerontol 2000; 36: 1749-1759.
17. Khosla S, Peterson Jm, Egan K et al. Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab 1994; 79: 707-711.
18. Verbruggen A, De Clerck LS, Bridts CH et al. Flow cytometrical determination of interleukin IB, interleukin-6 and tumour necrosis faktor-α in monocytes of rheumatoid arthritis patients; relation with parameters of osteoporosis. Cytokine 1999; 11: 869-874.
19. Langeu U, Teichmann J, Stracke H. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 2000; 29: 5507-5511.
20. Delmas PD. Biochemical markers of bone turnover I: Theoretical consideration and clinical use in osteoporosis. Am J Med 1993; 95; 5-11.
21. Tekin NS, Ozdolap S, Sarikaya S et al. Bone mineral density and bone turnover markers of patients with Behcet's disease J Eur Acad Dermatol Venereol 2007; 2: 25-29.
22. Abrahamsen B, Bonnevie-Nielsen V, Ebbesen EN et al. Cytokines and bone loss in a 5 year longitudinal study-hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin 1-receptor antagonist: the Danish osteoporosis prevention Study: J Bone Miner Res 2000; 15: 1545-1554.
23. Joffe I, Epstein S. Osteoporosis associated with rheumatoid arthritis: Pathogenesis and management. Semin Arthritis Rheum 1991; 20: 256-272.